TLDR Biotech aims to be your one-stop source for biotech and pharma updates - all with one daily email.

I’m always looking to make these news compilations more informative, impactful, and easy to navigate.

So if you have any feedback on what you like (or don’t), I’d love to hear from you! 📣

And if you like these newsletters and think a friend or colleague would benefit, please share this with them! ♻️

(You can also reach out to me on LinkedIn)

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

One last thing; I know paywalls can be annoying, so there’s a [Paywall] tag for any news stories behind one.

THE GOOD
Approvals & Labels

Novo Nordisk lands NMPA (China) approval for Wegovy
GLP-1, obesity, weight loss - Read more

NMPA also approves expanded label for AstraZeneca’s Tagrisso
Small molecule, lung cancer - Read more

FDA still open to handing Dizal Pharma an accelerated approval
Small molecule, lung cancer - Read more

Abbvie, Genmab handed FDA accelerated approval, label expansion
Bi-specific T-cell engager, follicular lymphoma, cancer - Read more

Verona Pharma scores FDA approval for COPD treatment
Small molecule, chronic obstructive pulmonary disease (COPD) - Read more

THE GOOD
Business Development

Just - Evotec Biologics lands $39M DOD project
Monoclonal antibody, accelerated development and manufacturing framework - Read more 

THE GOOD
Clinical Trials

Savara reports positive lung disease Ph3 data
Recombinant protein, autoimmune pulmonary alveolar proteinosis - Read more

Allakos touts positive Ph1 data in mast cell inhibition therapy
Monoclonal antibody, mast cell-driven diseases, asthma - Read more

Werewolf Therapeutics has promising Ph1 IL-12 prodrug data
Small molecule, non-hodgkin lymphoma, solid tumor, cancer - Read more

THE GOOD
Fundraises

Curie.Bio $380M Pro Rata Series A Fund
Venture capital, therapeutics investment - Read more

Formation Bio $372M Series D
AI, asset acquisition, workflow automation - Read more

Augustine Therapeutics €17M ($18.1M) Series A
Small molecule, peripheral and CNS diseases - Read more

Taysha Gene Therapies $75 public offering
AAV gene therapy, Rett syndrome - Read more

THE GOOD
Investments

GenScript ProBio debuts new plasmid and viral vector manufacturing site
Cell therapy, gene therapy, manufacturing - Read more

THE GOOD
Mergers & Acquisitions

SK Bioscience buys controlling stake in IDK Biologika for ₩339B ($244M)
CDMO, vaccine manufacturing - Read more

Dr. Reddy’s buys nicotine replacement division from Haleon
Nicotine replacement, smoking cessation, consumer health - Read more

Insud Pharma and Agile Therapeutics agree on a merger
Small molecule, contraceptive, women’s health - Read more

THE GOOD
Partnerships

Slope and big pharma names come together for the Biospecimen Management Consortium
Biospecimen lifecycle and regulations, industry standardization - Read more

THE GOOD
Politics & Policy

Medicare patients poised to pay less on 64 drugs whose price increases outpaced inflation
Drug pricing, medicare rebates - Read more

Supreme Court poised to reject Idaho’s near-total abortion ban
Women’s health, abortion - Read more [Paywall]

THE GOOD
Public Health

CDC modifies up RSV vaccine recommendation for older adults
Vaccine, respiratory syncytial virus - Read more

THE GOOD
Regulatory

FDA publishes clinical trial diversity draft guidance
Clinical trial recruitment, patient population diversity - Read more

EMA outlines action plan to tackle GLP-1 shortages
GLP-1, obesity, diabetes, drug shortages - Read more

THE GOOD
Research

Large scale DNA editing but without CRISPR; a new tool does just that
Gene-editing, DNA bridges - Read more

3D printed meds? Might not be as far-fetched as you think; study
Additive manufacturing, quality by design, point-of-care - Read more

THE GOOD
Strategic Plans

Optum Rx might be the new biosimilar player in town
Biosimilars, prescription drug benefit provider - Read more [Paywall]

ENJOYING THESE NEWSLETTERS?
Consider an optional paid subscription.

It’s a lot of work to put together a daily newsletter, and it’s currently just me writing these things (+ one part-time contractor - no fancy editing team!).

If you’re getting value out of these daily compilations, please consider a paid subscription (only $5/month) to support my continued work on this project.

THE BAD
Clinical Trials

Novo Nordisk suffers an $816M oof after Ph3 kidney disease failure
Small molecule, kidney disease, systolic blood pressure - Read more

Moderna stock takes a beating after their RSV vaccine’s long-term efficacy doesn’t stand-up to rivals’
Vaccine, respiratory syncytial virus - Read more

THE UGLY
Clinical Trials

Lyell Immunopharma Ph1 patient death spurs change of plans
CAR-T, solid tumor, lung cancer, breast cancer - Read more

THE UGLY
Lawsuits

Amarin resurrects Hikma Pharmaceuticals patent lawsuit
Patent law, small molecule, cardiovascular risk, hypertriglyceridemia - Read more

Arkansas drags Optum and Express Scripts into opioid epidemic lawsuit
Pharmacy benefit manager, opioid epidemic - Read more

THE UGLY
Patient Access

Mail order drugs, turns out, are more expensive - Read more [Paywall]

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

Want to sponsor this newsletter and reach an audience of 450+ biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.